Sulfonamide resistance in pigs is now traceable to a single amino acid change. A dihydropteroate synthase (DHPS) mutation at codon 57 (P57S) appeared in 91.8% and 87.5% of two swine Pneumocystis variants. Functional tests showed reduced susceptibility to sulfamethazine and sulfanilamide, but not to sulfadiazine or sulfamethoxazole.
Why sulfonamide resistance in pigs matters at the molecule level
Sulfonamides block folate synthesis. The drug competes with para-aminobenzoate for the DHPS active site, and a partner such as trimethoprim or diaveridine then blocks dihydrofolate reductase (DHFR), the next enzyme along. Change the shape of that first target and the whole combination gets weaker. That is the real reason to care about sulfonamide resistance in pigs: one point mutation can wear down a drug class that farms still lean on for bacterial and coccidial infections.
On a commercial unit these compounds arrive as medicated premix, soluble powder, or drinking-water formulations. Sulfamethazine (also spelled sulfadimidine) and sulfadiazine are two of the most common. Pigs see these molecules over and over, so anything living in the lung sees them too. Pneumocystis suis, an opportunistic fungus that colonizes mammalian lungs, is exactly that kind of bystander. Read its target genes and you get a surprisingly clear signal about whether drug pressure is picking out resistance.
Study design and sampling
Element | Detail |
Organism | Pneumocystis suis from pig and wild boar lungs |
Genes examined | dhps (dihydropteroate synthase) and dhfr (dihydrofolate reductase) |
Method | PCR amplification, Sanger sequencing, comparison with Pneumocystis jirovecii reference sequences |
Functional test | Heterologous complementation in Escherichia coli |
Structural test | Computational modelling of wild-type and mutant DHPS proteins in the apo state |
Outcome measures | Mutation frequency, growth under each sulfonamide, substrate-site geometry |
Two distinct variants, called A and B, came out of the samples that amplified and sequenced cleanly. Both dhps and dhfr were read and lined up against the human-adapted species, so known resistance markers could be spotted.
DHPS P57S dominates both variants
Variant | dhps P57S frequency | dhfr mutations | Wild boar detection |
A | 91.8% of sequences | No relevant mutation | Absent |
B | 87.5% of sequences | No relevant mutation | Absent |
The missense change at codon 57 (proline to serine) turned up in both homozygous and heterozygous form. It sat at high frequency in each variant, which is what you would expect if something is actively keeping it around under drug pressure. In the human pathogen P. jirovecii, the matching change is a common marker tied to potential sulfonamide resistance. Seeing the same position altered in the pig organism makes the parallel hard to dismiss.
Here is a detail worth pausing on: dhfr carried no relevant mutation in either variant. The whole resistance signal sat in the DHPS target, not the second enzyme. If you are the one writing the formula, that changes your options. More trimethoprim or diaveridine will not fix a binding problem at DHPS.
Functional complementation: the drug-by-drug result
The best part is that the team did not stop at the sequence. They put wild-type and mutant DHPS into E. coli and checked whether each sulfonamide still worked. What came back was oddly selective.
Compound | Susceptibility with P57S | Interpretation |
Sulfanilamide | Reduced | Parent structure loses potency |
Sulfamethazine | Reduced | Direct hit to a veterinary mainstay |
Sulfadoxine | Reduced | Long-acting sulfonamide also affected |
Sulfadiazine | Not reduced | Binding preserved despite same enzyme change |
Sulfamethoxazole | Not reduced | Binding preserved despite same enzyme change |
One amino acid swap, and the class does not fail as a block. Sulfamethazine loses ground while sulfadiazine and sulfamethoxazole hold their position. That is the counterintuitive bit worth remembering: two molecules with the same mechanism and the same target can land on opposite sides of one mutation.
Why two sulfonamides kept their activity
The structural models help explain the split. Wild-type and mutant proteins were modelled in the apo state, and the P57S change left the substrate-binding site itself intact. What it did change was the local flexibility of residues in the region where sulfonamides bind. Picture a pocket that is still the right shape but a little more mobile along one edge. A molecule that can anchor in a different way still works; one that relies on a tight, fixed fit starts to slip.
That lines up with the functional readings. Sulfadiazine and sulfamethoxazole appear to tolerate the extra movement, while sulfamethazine and sulfadoxine do not. There is a usable rule hiding in here. When you find a dhps mutation, do not write off the whole class. Test the exact molecule you intend to put in the formulation.
The wild boar contrast
None of the wild boar samples carried P57S. These animals had no known drug exposure, and their DHPS sequences stayed in the wild-type form. Set that beside the farm pigs and you have a natural experiment in selection. Where the drug is used, the mutant is everywhere; where it is not, the mutant is gone.
That is consistent with an association between sulfonamide exposure and the selection of resistance-associated mutations. It is not proof of cause on its own, and the report says as much. But stack up a high mutation frequency, a match with a known human resistance marker, a measured loss of potency, and absence in unexposed animals, and you have a signal that hangs together.
Practical implications for swine formulations
- Treat dhps status as a product-selection variable. If P57S is common in a target herd, a sulfamethazine premix may underperform even at the correct dose.
- Keep a second molecule on the shelf. Sulfadiazine and sulfamethoxazole kept their activity in the complementation assay, so rotating to one of them is a reasonable move rather than walking away from sulfonamides.
- Do not try to fix a DHPS problem with more potentiator. With dhfr untouched, extra trimethoprim or diaveridine is aimed at the wrong step.
- Put a sequencing check into tolerance investigations. When a batch underdelivers in the field, a target-gene read tells you whether you are looking at a formulation fault or a resistance fault.
- Watch the drinking-water route. Soluble salts deliver the same active by a different path, and the same target mutation still applies.
Limitations
The sample was limited to lungs that amplified and sequenced successfully, so those frequency numbers describe that group rather than every animal in the source population. Functional testing used E. coli complementation, which isolates the enzyme but cannot reproduce lung tissue, immune pressure, or what happens to the drug inside a pig. The structural story comes from apo-state models, and a ligand-bound structure could shift the picture. One more thing: this organism is a lung colonizer, not the bacterial or coccidial pathogens that sulfonamides are licensed against in swine. Read its DHPS sequence as a sentinel for drug pressure, not a direct readout of clinical failure in those pathogens.
Bottom line
Sulfonamide resistance in pigs can come down to one DHPS codon. P57S showed up at 91.8% and 87.5% in two variants, was missing in unexposed wild boars, and cut susceptibility to sulfamethazine while leaving sulfadiazine and sulfamethoxazole active. If you are specifying a sulfonamide for feed or water, the takeaway is concrete: confirm which molecule still binds the target in circulation before you lock the formula.
FAQ
How do I read a DHPS P57S result in a pig sample?
Treat it as a target-site marker, not a full susceptibility report. In the sequenced variants, P57S appeared in 91.8% and 87.5% of reads and was linked to reduced activity of some, but not all, sulfonamides. Pair the sequence result with a functional or phenotypic check on the exact molecule you plan to formulate.
Does P57S make every sulfonamide useless?
No. Functional complementation showed reduced susceptibility to sulfanilamide, sulfamethazine, and sulfadoxine, while sulfadiazine and sulfamethoxazole kept their activity. The mutation changes the dynamics of the sulfonamide-binding region rather than destroying the pocket, so the outcome depends on the individual molecule.
Why did dhfr not contribute to resistance here?
Neither variant carried a relevant dhfr mutation. The resistance signal sat entirely in dhps. That means the folate pathway was compromised at the first enzyme, and raising the dose of a DHFR inhibitor such as trimethoprim or diaveridine would not restore the blocked step.
What does the wild boar result tell me?
P57S was absent from all wild boar samples, which came from animals without known drug exposure. The contrast with high frequencies in farm pigs is consistent with selection under sulfonamide use. It supports an association, not a proven cause, but the pattern is difficult to ignore when choosing a program.
Can I rotate from sulfamethazine to sulfadiazine?
The data support considering it. Sulfadiazine retained activity in the complementation test where sulfamethazine lost it, despite both acting on DHPS. Rotation should still be confirmed with local susceptibility data, because the mutation picture in one region may not match another.
Is sulfamethazine the same as sulfadimidine?
Yes. Sulfamethazine is the USAN spelling and sulfadimidine is the INN spelling for the same molecule. Both refer to the compound that showed reduced susceptibility in the functional assay, so check the certificate of analysis and the label spelling before assuming two suppliers offer different actives.
How should a premix maker respond to a suspected resistance problem?
First separate a formulation fault from a target-site fault. Check content uniformity and assay, then look at dhps sequence data from the affected herd. If P57S dominates, switch to a molecule that retained activity rather than increasing the inclusion rate of the failing one.
Does the formulation route change the risk?
The target mutation applies to the molecule, not the delivery system. Medicated premix, soluble powder, and drinking-water salts all present the same active to DHPS. Route affects dose and exposure, but it does not bypass a binding-site change.
How strong is the structural explanation?
The apo-state models showed an intact substrate site with altered flexibility in the sulfonamide-binding region. That is consistent with the functional data but is not a ligand-bound crystal structure. Treat the model as a plausible mechanism rather than a settled one.
What are the main limits of this evidence?
The sample was restricted to amplifiable lungs, functional work used a heterologous E. coli system, and the organism is a lung colonizer rather than a licensed target pathogen. Use the findings as a sentinel signal about drug pressure and as a prompt for molecule-specific testing, not as a clinical efficacy claim.
Should I test every batch for dhps mutations?
Not necessarily every batch. A reasonable trigger is a field performance drop, a herd with heavy historical sulfonamide use, or a new supply region. When the trigger is present, a target-gene read is fast and turns an ambiguous complaint into a concrete molecule-selection decision.
What is the single most useful takeaway for a formulator?
Do not treat sulfonamides as interchangeable under resistance pressure. One DHPS codon separated sulfamethazine from sulfadiazine and sulfamethoxazole in this work. Verify the molecule against the circulating target, then choose the salt and route that deliver it reliably.